Early relapse after high-dose chemotherapy rescued by tumor-free autologous peripheral blood stem cells in acute lymphoblastic leukemia: importance of monitoring for WT1-mRNA quantitatively.

Abstract

A 24-year-old woman who suffered from ALL with MLL gene rearrangement received high-dose chemotherapy followed by autologous PBSC transplantation during complete remission (CR). Reverse transcriptase-polymerase chain reaction (RT-PCR) used to detect MLL/LTG4 chimeric mRNA showed no minimal residual disease (MRD) in the graft or bone marrow at the transplantation. However, the leukemia relapsed four months after transplantation. Retrospective analysis of quantitative measurement of Wilms tumor gene (WT-1) mRNA showed an increased level in the bone marrow although it was within the normal range. These observations suggest that careful monitoring of MRD by quantitative measurement of WT-1 mRNA in addition to disease-specific chimeric mRNA is required to predict relapse.

• Authors: T Sakatani, C Shimazaki, H Hirai, A Okano, M Hatsuse, A Okamoto, R Takahashi, E Ashihara, T Inaba, H Yokota, K Nakahara, H Hirai, M Nakagawa
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 42 Issue 1-2 Pg. 225-9 (Jun 2001) ISSN: 1042-8194 [Print] United States
• PMID: 11699212 (Publication Type: Case Reports, Journal Article)

Chemical References

• RNA, Neoplasm
• WT1 Proteins

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Neoplasm, Residual (diagnosis)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (diagnosis, therapy)
• Prognosis
• RNA, Neoplasm (analysis)
• Recurrence
• Transplantation, Autologous
• WT1 Proteins (genetics)